

RESEARCH ARTICLE | APRIL 12 2023

COVID-19 infection causes insulin-resistance between hospitalised patients in Najaf governorate

Ahmed Alshawi ; Abtisam F. Al-Shukry; Haider Ali Mohammed; Taif Razzaq Majeed; Alkarrar Kais Abduljaleel; Mohammed Subhi Mohammed



+ Author & Article Information

AIP Conference Proceedings 2776, 020008 (2023)

<https://doi.org/10.1063/5.0135959>

A novel epidemic infection Coronavirus-19 (COVID-19) considered as one of the challenges in sustainable development. A new-onset of hyperglycaemia has been observed between many COVID-19 patients. The clear explanation of this elevation in fasting plasma glucose (FPG) was debuted. Here we investigate whether this increase is due to impaired insulin secretion or insulin resistance. 269 participants, group 1 (control, n = 46) group 2 (COVID-19 patients, n = 223). 27 Patients were excluded due to missing of their FPG results. FPG, liver enzymes (ALT, AST, and Alk. Phosphatase), b.urea, s.creatinine, s. insulin, C-peptide, D-dimer, and s.ferritin were measured. Our results showed that FPG was increased in 82% (161) patients and this increase was positively correlated with ferritin ($r=0.039$, P-value 0.0013). There is no correlation between FPG with liver enzymes (ALT and AST). The level of insulin hormone and c-peptide were normal. Because there were no increase in insulin or c-peptide and the only relationship was between FPG and ferritin. Therefore, we concluded that COVID-19 infection could cause insulin resistance.

Topics

[Sustainable development](#), [Electrolytes](#), [Diseases and conditions](#), [Coronaviruses](#), [Enzymes](#), [Hormones](#), [Organs](#), [Peptides](#), [Carbohydrates](#)

REFERENCES

1. A. Saghzadeh and N. Rezaei, *Expert review of clinical immunology* 16 (5), 465–470 (2020).
<https://doi.org/10.1080/1744666X.2020.1750954>
[Crossref](#) [PubMed](#)
2. S. Baloch, M. A. Baloch, T. Zheng and X. Pei, *The Tohoku journal of experimental medicine* 250 (4), 271–278 (2020). <https://doi.org/10.1620/tjem.250.271>
[Crossref](#) [PubMed](#)
3. A. A. Anjorin, *Asian Pacific Journal of Tropical Medicine* 13 (5), 199 (2020).
<https://doi.org/10.4103/1995-7645.281612>
[Crossref](#)
4. F. Liu, L. Li, M. Xu, J. Wu, D. Luo, Y. Zhu, B. Li, X. Song and X. Zhou, *Journal of clinical virology* 127, 104370 (2020). <https://doi.org/10.1016/j.jcv.2020.104370>
[Crossref](#) [PubMed](#)
5. Y. Tang, J. Liu, D. Zhang, Z. Xu, J. Ji and C. Wen, *Frontiers in immunology*, 1708 (2020).
<https://doi.org/10.3389/fimmu.2020.01708>
6. S. Felsenstein, J. A. Herbert, P. S. McNamara and C. M. Hedrich, *Clinical immunology* 215, 108448 (2020).
<https://doi.org/10.1016/j.clim.2020.108448>
[Crossref](#) [PubMed](#)
7. E. Prompetchara, C. Ketloy and T. Palaga, *Asian Pacific journal of allergy and immunology* 38 (1), 1–9 (2020).
[PubMed](#)
8. A.-S. A. F. Alshawi A, *Pharmacophore*. 12 (5), 85–91 (2021). <https://doi.org/10.51847/XvbnHl3XSA>
[Crossref](#)
9. A. K. Singh, R. Gupta, A. Ghosh and A. Misra, *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 14 (4), 303–310 (2020). <https://doi.org/10.1016/j.dsx.2020.04.004>
[Crossref](#)
10. A. Hussain, B. Bhowmik and N. C. do Vale Moreira, *Diabetes research and clinical practice* 162, 108142 (2020).

<https://doi.org/10.1016/j.diabres.2020.108142>

[Crossref](#) [PubMed](#)

11. M. Peimani, F. Bandarian, N. Namazi and E. Nasli-Esfahani, *Journal of Diabetes & Metabolic Disorders*, 1–8 (2022).

12. E. L. Schiffrin, J. M. Flack, S. Ito, P. Muntner and R. C. Webb, (Oxford University Press US, 2020), Vol. 33, pp. 373–374.

13. J. Yang, Y. Feng, M. Yuan, S. Yuan, H. Fu, B. Wu, G. Sun, G. Yang, X. Zhang and L. Wang, *Diabetic medicine* 23 (6), 623–628 (2006).

<https://doi.org/10.1111/j.1464-5491.2006.01861.x>

[Crossref](#) [PubMed](#)

14. A. K. Singh and R. Singh, *Diabetes research and clinical practice* 167, 108382 (2020).

<https://doi.org/10.1016/j.diabres.2020.108382>

[Crossref](#) [PubMed](#)

15. F. Rubino, S. A. Amiel, P. Zimmet, G. Alberti, S. Bornstein, R. H. Eckel, G. Mingrone, B. Boehm, M. E. Cooper and Z. Chai, *New England Journal of Medicine* 383 (8), 789–790 (2020). <https://doi.org/10.1056/NEJMc2018688>

[Crossref](#) [PubMed](#)

16. D. R. Matthews, J. Hosker, A. Rudenski, B. Naylor, D. Treacher and R. Turner, *Diabetologia* 28 (7), 412–419 (1985). <https://doi.org/10.1007/BF00280883>

[Crossref](#) [PubMed](#)

17. J. Cacho, J. Sevillano, J. de Castro, E. Herrera and M. Ramos, *American journal of physiology-endocrinology and metabolism* 295 (5), E1269–E1276 (2008).

<https://doi.org/10.1152/ajpendo.90207.2008>

[Crossref](#) [PubMed](#)

18. A. Katz, S. S. Nambi, K. Mather, A. D. Baron, D. A. Follmann, G. Sullivan and M. J. Quon, *The Journal of Clinical Endocrinology & Metabolism* 85 (7), 2402–2410 (2000). <https://doi.org/10.1210/jcem.85.7.6661>

[Crossref](#)

19. K. Polak, A. Czyzyk, T. Simoncini and B. Meczekalski,

Journal of endocrinological investigation 40 (1), 1–8

(2017). <https://doi.org/10.1007/s40618-016-0523-8>

[Crossref](#)

[PubMed](#)

20. Q. Tang, X. Li, P. Song and L. Xu, *Drug discoveries & therapeutics* 9 (6), 380–385 (2015).

<https://doi.org/10.5582/ddt.2015.01207>

[Crossref](#)

21. S. Grycel, A. R. Markowski, H. R. Hady, P. Zabielski, I. Kojta, M. Imierska, J. Górska and A. U. Blachnio-Zabielska, *Nutrition* 63, 126–133 (2019).

<https://doi.org/10.1016/j.nut.2019.01.019>

[Crossref](#)

[PubMed](#)

22. Q. Cai, D. Huang, H. Yu, Z. Zhu, Z. Xia, Y. Su, Z. Li, G. Zhou, J. Gou and J. Qu, *Journal of hepatology* 73 (3), 566–574 (2020). <https://doi.org/10.1016/j.jhep.2020.04.006>

[Crossref](#)

[PubMed](#)

23. J. Chen, C. Wu, X. Wang, J. Yu and Z. Sun, *Frontiers in endocrinology*, 732 (2020).

24. J.-K. Yang, S.-S. Lin, X.-J. Ji and L.-M. Guo, *Acta diabetologica* 47 (3), 193–199 (2010).

<https://doi.org/10.1007/s00592-009-0109-4>

[Crossref](#)

[PubMed](#)

25. Y. J. Chee, S. J. H. Ng and E. Yeoh, *Diabetes research and clinical practice* 164, 108166 (2020).

<https://doi.org/10.1016/j.diabres.2020.108166>

[Crossref](#)

[PubMed](#)

26. J. Li, X. Wang, J. Chen, X. Zuo, H. Zhang and A. Deng, *Diabetes, Obesity and Metabolism* 22 (10), 1935–1941 (2020). <https://doi.org/10.1111/dom.14057>

[Crossref](#)

27. H. Ren, Y. Yang, F. Wang, Y. Yan, X. Shi, K. Dong, X. Yu and S. Zhang, *Cardiovascular diabetology* 19 (1), 1–8 (2020). <https://doi.org/10.1186/s12933-020-01035-2>

[Crossref](#)

[PubMed](#)

28. H. Xu, L. Zhong, J. Deng, J. Peng, H. Dan, X. Zeng, T. Li and Q. Chen, *International journal of oral science* 12 (1),

1–5 (2020). <https://doi.org/10.1038/s41368-019-0067-9>

[Crossref](#)

[PubMed](#)

29. B. J. Hoogwerf, *Cleveland Clinic Journal of Medicine* 87 (2), 100–108 (2020).

<https://doi.org/10.3949/ccjm.87a.19020>

[Crossref](#)

[PubMed](#)

30. S. Hörber, P. Achenbach, E. Schleicher and A. Peter, *Biotechnology advances* 39, 107359 (2020).

<https://doi.org/10.1016/j.biotechadv.2019.02.015>

[Crossref](#)

[PubMed](#)

31. M. Wang, A. Zhao, I. M. Y. Szeto, W. Wu, Z. Ren, T. Li, H. Feng, P. Wang, Y. Wang and Y. Zhang, *Food Science & Nutrition* 8 (3), 1406–1414 (2020).

<https://doi.org/10.1002/fsn3.1408>

[Crossref](#)

32. M. Cappellini, K. Musallam and A. Taher, *Journal of internal medicine* 287 (2), 153–170 (2020).

<https://doi.org/10.1111/joim.13004>

[Crossref](#)

[PubMed](#)

33. C. Camaschella, A. Nai and L. Silvestri, *Haematologica* 105 (2), 260 (2020).

<https://doi.org/10.3324/haematol.2019.232124>

[Crossref](#)

[PubMed](#)

34. L. Yu, J. Yan, Q. Zhang, H. Lin, L. Zhu, Q. Liu and C. Zhao, *Journal of Diabetes Research* 2020 (2020).

35. W. Zhang, Y. Tang, J. Huang, Y. Yang, Q. Yang and H. Hu, *Journal of clinical biochemistry and nutrition*, 19–103 (2020).

This content is only available via PDF.



©2023 Authors. Published by AIP Publishing.